Ci-DMS MES in action
Paper-based delays?
Paper-based process-driven delays are no longer an issue for Ci-DMS MES customers ($300 B value lost in 2018*).
Our MES solution highlights deviations enabling batch release by exception and interfaces with the Enterprise Resource Planning (ERP) system to automatically update stock records.
*Source: various including McKinsey & Co & Pharmaceutical Engineering.
Can you afford the costs of a batch failure?
With increasing demands for higher output, and lower overheads, can you afford the costs associated with a batch failure? (typically, 47% First Pass Yield (FPY) rate (zero defects) in paper-based pharmaceutical manufacturing*)
Ci-DMS MES uses the Right FIrst TIme method, manufacturing errors/deviations are highlighted when they occur, and the batch cannot be continued until the issue is resolved, safeguarding against batch failure and increasing the FPY rate.
A global Ci-DMS MES customer saves in excess of $400K per year and avoids two potential failed batches per month in their USA plant.
*source: various including McKinsey & Co & Pharmaceutical Engineering.
What can we help you with?
Why MES
Contact UsEliminating human error
Contact UsDriving compliance
Contact UsImproving productivity
Contact UsEnsuring data integrity
Contact UsWhy CI Precision
Contact UsAligning with your IT strategy
Contact UsManufacturing Management Systems (MMS)
Contact UsCreating a business case
Contact UsHave you counted your cost to comply with the Falsified Medicines Directive?
Upwards of $1.77 can be added to the cost per a drug package as a result of the high levels of investment needed to comply with the Falsified Medicines Directive (FMD)*
Ci-DMS MES is configured and validated for compliance, electronic records and processes improve data integrity whilst reducing our customers’ overheads associated with maintaining compliance.
In most cases, a return on investment is achieved within one year.
*source: Capgemini Consulting
Case Studies
Large OTC & healthcare medicines manufacturer
The world’s largest manufacturer of OTC & healthcare medicines has made significant savings in ensuring quality control and eliminating QC checking.
MoreLeading research-based pharmaceutical company
One of the world's leading research-based pharmaceutical companies has benefited from having Ci-DMS in operation and fully supported for over 7 years maintaining accurate stock control.
MoreBritish multinational consumer goods company
Adopted as the global standard at a British multinational consumer goods company, Ci-DMS MES was implemented on budget, on time with a Return on Investment within a year.
MoreCost of Goods Sold too high?
For many paper-based manufacturers Cost of Goods Sold (COGS) is at least 27% of sales and can be as high as 45%*.
Much of this cost is in post-batch analysis and reporting and is often an intense and demanding activity requiring highly trained people.
Ci-DMS MES extensive and real-time management reporting capabilities significantly reduce the costs of post-production analysis. Electronic records improve data integrity, reduce the risk of human error, and electronic signatures ensure FDA / EMA compliance.
*source: Various including McKinsey & Co and J Pharm Innov
Solutions
White Paper - Benefits of a computerised dispensary
Ensure that the correct quantity of an approved raw material of known origin and quality is used during the manufacture of pharmaceutical products.
Next Steps
To find out more, please contact our team of MES specialists.
Get contact detailsMeet us at an exhibition